The online version of this article (doi:10.1186/1758-5996-6-110) contains supplementary material, which is available to authorized users.
MN and AG have received a research grant from Novo Nordisk. MN has received speaker honoraria from Eli Lilly and Novo Nordisk.
KI conceptualized the idea for the study, collected the data, performed a literature review, and wrote the manuscript. TT, MK, and RYH participated in the design of the study, participated in the discussion, and was involved in drafting the manuscript. MG and AG were involved in performing the statistical analysis, participated in the discussion, and were involved in drafting the manuscript. HN and HK participated in the discussion. MN presented the initial concept and reviewed the manuscript. All the authors have read and approved the final manuscript.
Glucagon-like peptide-1 (GLP-1) receptor agonists can maintain good glycemic control in some diabetic. Here we compared the clinical characteristics and parameters reflecting glucose metabolism at the time of the initiation of GLP-1 receptor agonist therapy between patients who responded well to therapy and those who did not.
The records of 43 patients with type 2 diabetes who started receiving GLP-1 receptor agonist therapy during hospitalization were retrospectively reviewed. Glucagon stimulation tests were performed, and patients were started on liraglutide or exenatide therapy. Preprandial blood glucose levels were measured on days 2 and 3 of GLP-1 receptor agonist therapy. We used the Cox proportional hazard model to compare clinical parameters between responders (HbA1c level <8% at more than 3 months after the initiation of treatment) and non-responders (HbA1c level ≥8% at more than 3 months after the initiation of treatment or a switch to insulin therapy at any time).
Twenty-six of the 43 patients were classified as non-responders. At baseline, mean HbA1c levels were 9.9% among responders and 9.7% among non-responders. Compared with treatment with only diet or metformin, the hazard ratio [HR] for non-response was 5.3 (95% confidence interval [CI]: 1.16-24.6, P = 0.03) for insulin therapy and 5.0 (95% CI: 1.13-22.16, P = 0.03) for sulfonylurea therapy. Compared with the lowest tertile, the HRs for non-response in the highest tertile were 3.1 (95% CI: 1.04-8.97, P = 0.04) for the mean preprandial blood glucose level on days 2 and 3 and 3.4 (95% CI: 1.05-11.01, P = 0.04) for the body mass index. The response was not significantly associated with the duration of diabetes or the glucagon stimulation test results. A receiver operating curve analysis showed that the mean preprandial blood glucose level had the highest area under the curve value (=0.72) for the prediction of non-responders.
In patients with poorly controlled diabetes, the response to GLP-1 receptor agonist therapy was significantly associated with the treatment used before the initiation of therapy, the body mass index, and the mean preprandial blood glucose level during the 2 days after the initiation of therapy.
Authors’ original file for figure 113098_2014_370_MOESM1_ESM.pdf
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012, 35: 1364-1379. 10.2337/dc12-0413. PubMedCentralCrossRefPubMed
Takehiro Kawata AK, Kubota A, Maeda H, Amamiya H, Takai M, Kaneshige H, Minagawa F, Iemitsu K, Kaneshiro M, Ishikawa M, Takeda H, Takuma T, Mokubo A, Machimura H, Obana M, Miyakawa M, Naka Y, Suzuki D, Terauchi Y, Toyoda M, Tanaka Y, Matsuba I: Is a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus patients?. J Clin Med Res. 2014, 6: 138-144. PubMedCentralPubMed
Nambu T, Matsuda Y, Matsuo K, Kanai Y, Yonemitsu S, Muro S, Oki S: Liraglutide administration in type 2 diabetic patients who either received no previous treatment or were treated with an oral hypoglycemic agent showed greater efficacy than that in patients switching from insulin. J Diabetes Investig. 2012, 4: 69-77. PubMedCentralCrossRefPubMed
Kozawa J, Inoue K, Iwamoto R, Kurashiki Y, Okauchi Y, Kashine S, Kitamura T, Maeda N, Okita K, Iwahashi H, Funahashi T, Imagawa A, Shimomura I: Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity. J Diabetes Investig. 2012, 3: 294-297. 10.1111/j.2040-1124.2011.00168.x. PubMedCentralCrossRefPubMed
Takabe M, Matsuda T, Hirota Y, Hashimoto N, Nakamura T, Sakaguchi K, Ogawa W, Seino S: C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment. Diabetes Res Clin Pract. 2012, 98: e32-e35. 10.1016/j.diabres.2012.09.036. CrossRefPubMed
Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, Hussein MA: Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care. 2011, 34: 90-95. 10.2337/dc10-1393. PubMedCentralCrossRefPubMed
Rosenstock J, Shenouda SK, Bergenstal RM, Buse JB, Glass LC, Heilmann CR, Kwan AY, MacConell LA, Hoogwerf BJ: Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care. 2012, 35: 955-958. 10.2337/dc11-1434. PubMedCentralCrossRefPubMed
Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Hiroshi I, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H: International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program valu. J Diabetes Investig. 2012, 3: 39-40. 10.1111/j.2040-1124.2012.00207.x. PubMedCentralCrossRefPubMed
He L: Insulin secretagogues: old and new. Diabetes Rev. 1999, 7: 139-153.
Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009, 373: 473-481. 10.1016/S0140-6736(08)61246-5. CrossRefPubMed
Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR: Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab. 2013, 15: 204-212. 10.1111/dom.12012. CrossRefPubMed
- Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II